The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
In a move reflecting institutional confidence in healthcare dividends, Abbott Laboratories' stock stabilized following its recent inclusion in the Schwab U.S. Dividend Equity ETF (SCHD). Analysts maintain a 'Moderate Buy' rating on the stock with a target price of approximately $119.09, according to reports. This stabilization follows a reallocation towards the healthcare sector by the SCHD ETF, which has helped offset some institutional selling by pension funds.
The inclusion comes as major healthcare peers experience mixed price action, with competitors like Johnson & Johnson and Danaher trading near their annual averages per market data. Compared to the previous quarter, Abbott's medical device segment has shown continued growth, enhancing its appeal to dividend-focused funds like SCHD. This ETF-driven liquidity has provided a crucial buffer against selling pressure from large public institutional portfolios looking to diversify.
Sign in to access this content
Sign InAs of the close in late May 2026, ABT shares remain at levels consistent with analyst price targets. Traders are now looking toward the release of the U.S. Core PCE Price Index on May 28, 2026, which could impact sentiment for defensive healthcare stocks. Additionally, the U.S. GDP growth rate data scheduled for the same day will be a key catalyst for assessing broader sector valuation and consumer healthcare spending.